Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said during a teleconference with journalists that the trials will take place in various countries around the world.
“We will conduct clinical trials not only in Russia but also the United Arab Emirates, Saudi Arabia, the Philippines, probably in Brazil as well as in India,” Dmitriev said. He also said that a delegation from the Saudi Ministry of Health would travel to Moscow next week.
Experts are skeptical about how quickly the vaccine, named Sputnik V, was registered and how few details about the investigation were released.
Dmitriev said on Thursday that Russia would try to respond to Western criticism over the lack of information about its vaccine candidate by publishing a detailed scientific paper in August. He refused to name the publication where the study would be published.
He also refused to give an exact number for how many people have already tested the vaccine.
To date, Russia has not released scientific data on its tests and CNN is unable to verify the vaccine’s claims about safety or effectiveness.
Upcoming clinical trials are underway to assess the “epidemic effectiveness” of the vaccine, said Denis Logunov, deputy director of scientific work at the Gamaleya Research Institute of Epidemiology and Microbiology, which is developing the Russian candidate for vaccine Covid-19, said on Thursday.
Alexander Ginsburg, director of the Gamaleya Research Institute of Epidemiology and Microbiology, described on Thursday how the vaccine is given in two doses and involves the use of a different adenovirus for each of the two doses.
Dmitriev said that “Russia is open to international cooperation” and “we believe that other faxes will come and the more faxes we get better at.”
.
